Investing in Hemophilia Care: Benefits and Costs for Patients and Society

Seminars in Hematology

Volumn 45, Issue SUPPL. 1, 2008, Pages

  Scalone, Luciana ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING INHIBITOR; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ARTHROPATHY; ARTICLE; COST MINIMIZATION ANALYSIS; COST OF ILLNESS; DRUG COST; FUNCTIONAL STATUS; HEALTH CARE; HEALTH CARE COST; HEALTH PROGRAM; HEMOPHILIA; HOSPITAL COST; HUMAN; MEDICAL DECISION MAKING; PATIENT CARE; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME; TREATMENT PLANNING; WELLBEING;

COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HEMOPHILIA A; HUMANS; QUALITY OF LIFE;

EID: 44649092579     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2008.03.019     Document Type: Article

References (35)

1. Triemstra M., Rosendaal F.R., Smit C., Van der Ploeg H.M., and Briët E. Mortality in patients with hemophilia. Changes in a Dutch population from 1986 to 1992 and 1973 to 1986. Ann Intern Med 123 (1995) 823-827
2. Leissinger C., Wulff K., and Abdou A. Inhibitor prevalence and association with morbidity in severe hemophilia A patients. Blood 98 (2001) 535 (abstr)
3. Soucie J.M., Cianfrini C., Janco R.L., Kulkarni R., Hambleton J., Evatt B., et al. Joint range-of-motion limitations among young males with hemophilia: Prevalence and risk factors. Blood 103 (2004) 2467-2473
4. Morfini M., Haya S., Tagariello G., Pollmann H., Quintana M., Siegmund B., et al. European study on orthopaedic status of haemophilia patients with inhibitors. Haemophilia 13 (2007) 606-612
5. Darby S.C., Keeling D.M., Spooner R.J., Wan Kan S., Giangrande P.L., Collins P.W., et al. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99. J Thromb Haemost 2 (2004) 1047-1054
6. Quintana-Molina M., Martínez-Bahamonde F., González-García E., Romero-Garrido J., Villar-Camacho A., Jiménez-Yuste V., et al. Surgery in haemophilic patients with inhibitor: 20 years of experience. Haemophilia 10 suppl 2 (2004) 30-40
7. Tjønnfjord G.E., Brinch L., Gedde-Dahl T., and Brosstad F.R. Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX. Haemophilia 10 (2004) 174-178
8. Dimichele D. Inhibitors: Resolving diagnostic and therapeutic dilemmas. Haemophilia 8 (2002) 280-287
9. O'Connell N., McMahon C., Smith J., Khair K., Hann I., Liesner R., et al. Recombinant factor VIIa in the management of surgery and acute bleeding episodes in children with haemophilia and high responding inhibitors. Br J Haematol 116 (2002) 632-635
10. Santagostino E., Gringeri A., and Mannucci P.M. State of care for hemophilia in pediatric patients. Paediatr Drugs 4 (2002) 149-157
11. Ingerslev J. Efficacy and safety of recombinant factor VIIa in the prophylaxis of bleeding in various surgical procedures in hemophilic patients with factor VIII and factor IX inhibitors. Semin Thromb Hemost 26 (2000) 425-432
12. Leissinger C.A. Use of prothrombin complex concentrates and activated prothrombin complex concentrates as prophylactic therapy in haemophilia patients with inhibitors. Haemophilia 5 suppl 3 (1999) 25-32
13. Shapiro A., Gilchrist G.S., Hoots W.K., Cooper H.A., and Gastineau D.A. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophlia patients with inhibitors undergoing surgery. Thromb Haemost 80 (1998) 773-778
14. Lusher J., Ingerslev J., Roberts H., and Hedner U. Clinical experience with recombinant factor VIIa. Blood Coagul Fibrinolysis 9 (1998) 119-128
15. Negrier C., Goudemand J., Sultan Y., Bertrand M., Rothschild C., and Lauroua P. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Inhibitor Bypassing Activity. Thromb Haemost 77 (1997) 1113-1119
16. Mariani G., Ghirardini A., and Bellocco R. Immune tolerance in hemophilia-Principal results from the international registry. Report of the factor VIII and IX Subcommittee. Thromb Haemost 72 (1994) 155-158
17. Hedner U., Glazer S., Pingel K., Alberts K.A., Blombäck M., Schulman S., et al. Successful use of rFVIIa in a patient with severe haemophilia A subjected to synovectomy. Lancet 2 (1988) 1193
18. Hutchinson R.J., Penner J.A., and Hensinger R.N. Anti-inhibitor coagulant complex (Autoplex) in hemophilia inhibitor patients undergoing synovectomy. Pediatrics 71 (1983) 631-633
19. Sjamsoedin L.J., Heijnen L., Mauser-Bunschoten E.P., van Geijlswijk J.L., van Houwelingen H., van Asten P., et al. The effect of activated prothrombin complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial. N Engl J Med 305 (1981) 717-721
20. Gringeri A., Mantovani L.G., Scalone L., and Mannucci P.M. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: The COCIS study group. Blood 102 (2003) 2358-2363
21. Scalone L., Mantovani L.G., Mannucci P.M., and Gringeri A. The COCIS Study Investigators: Quality of life is associated to the orthopaedic status in haemophilic patients with inhibitors. Haemophilia 12 (2006) 154-162
22. Scalone L., Gringeri A., Mannucci P.M., Von Mackensen S., and Mantovani L.G. Costs and quality of life in hemophilia: Comparison between patients with and patients without inhibitors. Value Health 8 (2005) A5 (abstr)
23. Morfini M., Auerswald G., Kobelt R.A., Rivolta G.F., Rodriguez-Martorell J., Scaraggi F.A., et al. Prophylactic treatment of haemophilia patients with inhibitors: Clinical experience with recombinant factor VIIa in European Haemophilia Centres. Haemophilia 13 (2007) 502-507
24. Valentino L.A. FEIBA prophylaxis for patients with haemophilia and inhibitors. Haemophilia 12 suppl 5 (2006) 26-31
25. Stephens J.M., Joshi A.V., Sumner M., and Botteman M.F. Health economic review of recombinant activated factor VII for treatment of bleeding episodes in hemophilia patients with inhibitors. Expert Opin Pharmacother 8 (2007) 1127-1136
26. Solimeno L.P., Perfetto O.S., Pasta G., and Santagostino E. Total joint replacement in patients with inhibitors. Haemophilia 12 suppl 3 (2006) 113-116
27. Allen G., and Aledort L. Therapeutic decision-making in inhibitor patients. Am J Hematol 81 (2006) 71-72
28. Astermark J., Morado M., Rocino A., van den Berg H.M., von Depka M., Gringeri A., et al. Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors. Haemophilia 12 (2006) 363-371
29. Monahan P.E., and Aledort L.M. Hemophilia Inhibitor Study Group: Factors affecting choice of hemostatic agent for the hemophilia patient with an inhibitor antibody. Am J Hematol 77 (2004) 346-350
30. Astermark J., Rocino A., Von Depka M., Van Den Berg H.M., Gringeri A., Mantovani L.G., et al. Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors. Haemophilia 13 (2007) 38-45
31. Konkle B.A., Ebbesen L.S., Erhardtsen E., Bianco R.P., Lissitchkov T., Rusen L., et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 5 (2007) 1904-1913
32. Leissinger C.A. Prophylaxis in haemophilia patients with inhibitors. Haemophilia 12 suppl 6 (2006) 67-73
33. Samuelson P.A., and Nordhaus W.D. Economics (2004), McGraw-Hill, Columbus, OH
34. Mantovani L.G., Monzini M.S., Mannucci P.M., Scalone L., Villa M., Gringeri A., et al. Differences between patients', physicians' and pharmacists' preferences for treatment products in haemophilia: A discrete choice experiment. Haemophilia 11 (2005) 589-597
35. Borghetti F., Gringeri A., Scalone L., von Mackensen S., and Mantovani L.G. Preferences towards coagulation factor concentrates used to treat hemophilic patients with inhibitors: The patients', physicians' and pharmacists' perspective. Haematologica 92 (2007) 225 (abstr)